Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
It has been studied and published for some time by different groups that inhibiting TLS DDR polymerase Pol eta (or Pol H, POLH, polymerase eta) can help reduce chemoresistance to chemotherapies like cisplatin, especially in ovarian cancer. This new research offers a related approach: instead of inhibiting Pol eta directly, inhibiting the PCNA-Pol eta PPI interface with a Pol eta-derived peptide. #oncology #therapeutics #drugdiscovery https://lnkd.in/g5DHFqXq